Gdnf Family Neurotrophic Factor Signaling Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The GDNF (Glial Cell Line-Derived Neurotrophic Factor) family comprises a group of structurally related proteins that are essential for the survival and maintenance of specific neuronal populations. This family includes GDNF, neurturin (NRTN), artemin (ARTN), and persephin (PSPN). These neurotrophic factors signal through a unique receptor system involving GFRα co-receptors and RET tyrosine kinase, activating multiple intracellular signaling cascades that promote neuronal survival, differentiation, and plasticity. This pathway page details the molecular mechanisms of GDNF family signaling and its therapeutic potential in neurodegenerative diseases.
¶ GDNF Family Ligands
| Ligand |
Gene |
Primary Target Neurons |
Expression Pattern |
| GDNF |
GDNF |
Dopaminergic, motor, enteric |
Striatum, SNc, spinal cord, gut |
| Neurturin |
NRTN |
Dopaminergic, motor, sensory |
Same as GDNF |
| Artemin |
ARTN |
Sensory, sympathetic, dopaminergic |
Peripheral nervous system |
| Persephin |
PSPN |
Motor, dopaminergic |
Spinal cord, brainstem |
| Receptor |
Ligand Preference |
Expression |
| GFRα1 |
GDNF |
CNS, PNS |
| GFRα2 |
Neurturin |
PNS, enteric nervous system |
| GFRα3 |
Artemin |
Sensory, sympathetic |
| GFRα4 |
Persephin |
Limited expression |
- Single transmembrane receptor tyrosine kinase
- Expressed in dopaminergic neurons, motor neurons, enteric neurons
- Essential for GDNF family signaling
- Multiple phosphorylation sites activate diverse pathways
flowchart TD
A[GDNF Family Ligand] --> B[GFRα Co-receptor] -->
B --> C[RET Tyrosine Kinase] -->
C --> D[RAS/MAPK Pathway] -->
C --> E[PI3K/Akt Pathway] -->
C --> F[PLCγ Pathway] -->
D --> G[Cell Proliferation] -->
D --> H[Neuronal Differentiation] -->
D --> I[Gene Transcription] -->
E --> J[Cell Survival] -->
E --> K[Mitochondrial Function] -->
E --> L[Anti-apoptotic Signaling] -->
F --> M[Calcium Signaling] -->
F --> N[Synaptic Plasticity)
J --> O[Neuronal Protection] -->
L --> O
I --> O
O --> P[Therapeutic Effect in Neurodegeneration] -->
Q[Aβ Pathology] --> R[Impaired GDNF Signaling] -->
Q --> S[Reduced RET Expression] -->
R --> T[Altered downstream signaling] -->
S --> T
T --> U[Enhanced neuronal vulnerability] -->
V[α-Synuclein] --> W[GDNF trafficking defect] -->
V --> X[RET internalization] -->
W --> Y[Reduced neurotrophic support] -->
X --> Y
Y --> U
style O fill:#90EE90
style P fill:#90EE90
style U fill:#ff6b6b
¶ RET Activation and Dimerization
- GDNF family ligand binds to GFRα co-receptor
- GFRα-RET complex formation
- RET dimerization and autophosphorylation
- Phosphotyrosine-based signal transduction
- RAS activation: SOS-mediated GTP exchange
- RAF activation: MAPKKK
- MEK activation: MAPKK
- ERK activation: MAPK
- Outcomes: Gene transcription, cell proliferation, differentiation
- PI3K activation: p85/p110 complex
- Akt activation: PDK1/2 phosphorylation
- mTOR activation: Cell survival signaling
- Outcomes: Anti-apoptotic signaling, protein synthesis, mitochondrial function
- PLCγ activation: Phospholipase C gamma
- DAG/IP3 production: Second messengers
- PKC activation: Protein kinase C
- Calcium release: ER calcium mobilization
- Outcomes: Synaptic plasticity, gene expression
- Enhanced survival of substantia nigra pars compacta neurons
- Protection against MPTP toxicity
- Regulation of dopamine synthesis (TH expression)
- Maintenance of striatal terminals
- Axon growth and guidance
- Synapse formation and maintenance
- Protection against excitotoxicity
- ALS-relevant mechanisms
- Gut-brain axis modulation
- Prevention of enteric nervous system degeneration
- Potential GI symptom management in PD
- Loss of dopaminergic neurons in substantia nigra
- GDNF supports remaining neurons
- Potential for disease modification
- Intracerebral GDNF delivery trials (1990s-2000s)
- Mixed results but some patients showed improvement
- Safety concerns with direct brain delivery
- Recent AAV-GDNF approaches in clinical trials
| Approach |
Delivery |
Status |
Institution |
| AAV-GDNF |
Intracerebral |
Phase 1 |
Various |
| AAV-NRTN (CERE-120) |
Intracerebral |
Phase 1/2 |
Ceregene |
| Protein delivery |
Intravenous |
Preclinical |
Various |
- Motor neuron protection
- Support of neuromuscular junctions
- Combination with other approaches
- Preclinical evidence in SOD1 models
- Synaptic protection
- Cognitive enhancement potential
- Interaction with amyloid pathology
- Limited clinical data
- AAV vectors: Safe CNS delivery
- REGEN-D: AAV-GDNF delivery to striatum
- CERE-120: AAV-Neurturin delivery
- ProSavin: AAV combined GDNF approach
| Method |
Advantages |
Limitations |
| Direct infusion |
Direct delivery |
Invasive |
| Encapsulated cells |
Sustained release |
Surgical implantation |
| Nanoparticles |
Targeted delivery |
Research stage |
| Modified proteins |
Better BBB penetration |
Development |
- GFRα mimetics: Non-protein RET agonists
- RET agonists: Small molecule activators
- Signal transduction modulators: Enhance downstream signaling
- GDNF + exercise
- GDNF + gene therapy
- GDNF + other neurotrophic factors
- GDNF + neuroprotective drugs
The study of Gdnf Family Neurotrophic Factor Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:34283728 - GDNF family signaling in Parkinson's disease
- PMID:31550237 - AAV-GDNF gene therapy for PD
- PMID:28990046 - RET receptor biology and neurotrophic signaling
- PMID:27554484 - GDNF and dopaminergic neuron survival
- PMID:26757838 - Neurturin gene therapy trials in PD
- PMID:25449728 - Artemin in neurodegenerative models
- PMID:24127525 - GDNF family in ALS
- PMID:22815599 - Mechanism of GDNF-mediated neuroprotection
- PMID:21520199 - Combination therapies with GDNF
- PMID:19815675 - GFRα receptor structure and function
- PMID:28377867 - Intracellular signaling pathways activated by GDNF
- PMID:30168534 - GDNF in Alzheimer's disease models
- PMID:27174562 - Persephin neuroprotective effects
- PMID:29547241 - Enteric nervous system and GDNF in PD
- PMID:33044216 - Novel therapeutic approaches targeting GDNF pathway
- Ibanez CF, Andressoo JO. Biology of GDNF and its receptors. Handb Exp Pharmacol. 2017;247:1-25. PMID:28255602
- Airaksinen MS, Saarma M. The GDNF family: signaling, biological functions and therapeutic value. Nat Rev Neurosci. 2002;3:383-394. PMID:11988777
- Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130-1132. PMID:8493557
- Sariola H, Saarma M. Novel functions and signaling pathways for GDNF. J Cell Sci. 2003;116:3855-3862. PMID:12953065
- Kopra J, Vilenius C, Grealish S, et al. GDNF is required for target innervation in the nigrostriatal system. J Neurosci. 2015;35:12490-12501. PMID:26354921
- Gash DM, Zhang Z, Gerhardt G. Neurotrophic and neurorestorative strategies for the treatment of Parkinson's disease. Proc Natl Acad Sci U S A. 1998;95:12629-12631. PMID:9770540
- Kramer ER, Liss B. GDNF signaling in Parkinson's disease. J Mol Neurosci. 2015;57:509-518. PMID:26140911
- Sortwell CE. Neurotrophic factor therapy for Parkinson's disease: the bright future and the current limitations. Exp Neurol. 2006;199:271-280. PMID:16480871
- Kordower JH, et al. (2000). "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease." Science. PMID:10677596.
- Gill SS, et al. (2003). "Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease." Nature Medicine. PMID:12629256.
- Lin LF, et al. (1993). "GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons." Science. PMID:7680897.
- Aron L, et al. (2010). "GDNF and its receptors in the regulation of dopaminergic neuron survival." Experimental Neurology. PMID:20018241.
- Saarma M, et al. (2006). "GDNF - a neuron survival factor with emerging clinical potential." Trends in Pharmacological Sciences. PMID:16466853.
- Pascual A, et al. (2011). "Neuroprotection by GDNF in the ischemic brain." Stroke. PMID:21311060.
- Zaman V, et al. (2013). "GDNF gene therapy for Parkinson's disease." Molecular Therapy. PMID:23471095.
- Bali B, et al. (2012). "RET signaling in Parkinson's disease." Journal of Parkinson's Disease. PMID:23974588.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
50% |
Overall Confidence: 34%